8-K: Cardiff Oncology Reports Strong Phase 2 Data for Onvansertib in RAS-Mutated Colorectal Cancer, Extends Cash Runway

Cardiff Oncology announced positive Phase 2 clinical trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer, showing a significant improvement in objective response rates and a dose-dependent effect, alongside a cash runway extended into Q1 2027.

Summary

• Cardiff Oncology reported financial results for the second quarter ended June 30, 2025, and provided a business update.
• The company announced positive data from the ongoing randomized Phase 2 CRDF-004 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• Confirmed Objective Response Rate (ORR) in the 30mg onvansertib dose arm was 49% (18 of 37 patients), compared to 30% (11 of 37 patients) in the control arm, representing a 19% improvement (p=0.018).
• Early Progression-Free Survival (PFS) data showed a trend favoring the 30mg onvansertib dose arm versus the control arm, with median PFS not yet reached.
• Onvansertib demonstrated dose-dependent increases across all efficacy endpoints, including ORR, Early Tumor Shrinkage (ETS), and Depth of Response (DpR).
• The company completed enrollment in the CRDF-004 trial, reaching the targeted enrollment of patients across 41 U.S. clinical sites.
• Cardiff Oncology appointed Dr. Roger Sidhu as Chief Medical Officer in June 2025.
• Positive data from an investigator-initiated trial of onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) was announced at ASCO 2025, showing a 40% ORR.
• A second U.S. patent (No. 12,263,173) was issued for the treatment of mCRC for bev-naive patients, with an expiration date no earlier than 2043.
• As of June 30, 2025, cash, cash equivalents, and short-term investments totaled approximately $71.0 million, projected to fund operations into Q1 2027.
• Net cash used in operating activities for Q2 2025 was $8.3 million, a decrease of $0.9 million from $9.2 million in Q2 2024.
• Total operating expenses for Q2 2025 were $14.9 million, an increase of $2.2 million from $12.7 million in Q2 2024, primarily due to CRDF-004 trial costs, other clinical programs, and key hires.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial data for onvansertib in a significant cancer indication, demonstrating a statistically significant improvement in ORR and favorable trends in PFS, ETS, and DpR. The drug's good tolerability, combined with an extended cash runway and strategic management appointment, indicates strong progress and future potential, positioning the company well for registrational trials.

Positives

• Onvansertib 30mg dose achieved a 49% confirmed Objective Response Rate (ORR) in first-line RAS-mutated mCRC, a 19% improvement over the 30% ORR in the control arm (p=0.018).
• Early Progression-Free Survival (PFS) data showed a favorable trend for the 30mg onvansertib dose arm, with median PFS not yet reached.
• Onvansertib demonstrated dose-dependent increases in efficacy across ORR, Early Tumor Shrinkage (ETS), and Depth of Response (DpR).
• The drug was well-tolerated in combination with chemotherapy and bevacizumab, with no major or unexpected toxicities.
• The CRDF-004 trial successfully completed patient enrollment.
• Cash, cash equivalents, and short-term investments of $71.0 million as of June 30, 2025, provide a projected cash runway into Q1 2027.
• Net cash used in operating activities decreased to $8.3 million in Q2 2025 from $9.2 million in Q2 2024.
• The appointment of Dr. Roger Sidhu as Chief Medical Officer brings over 20 years of oncology research, development, and regulatory strategy experience.
• Positive data from an investigator-initiated trial in metastatic triple-negative breast cancer (mTNBC) showed a 40% ORR for onvansertib plus paclitaxel.
• A new U.S. patent (No. 12,263,173) was issued for onvansertib in mCRC, extending protection until at least 2043.

Negatives

• Total operating expenses increased by $2.2 million to $14.9 million in Q2 2025 compared to Q2 2024, driven by clinical trial costs and new hires.
• Net loss increased to $13.943 million in Q2 2025 from $11.778 million in Q2 2024.

Risks

• Clinical trials involve a lengthy and expensive process with an uncertain outcome, and earlier study results may not predict future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude product candidate approval.
• Results of preclinical studies or clinical trials for the product candidate could be unfavorable or delayed.
• The company may need additional financing.
• Risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on information technology infrastructure, could harm financial condition and increase costs.
• Uncertainties exist regarding government or third-party payer reimbursement.
• Dependence on key personnel poses a risk.
• Limited experience in marketing and sales could hinder commercial success.
• Substantial competition exists in the oncology drug development space.
• Uncertainties of patent protection and litigation could impact intellectual property.
• Dependence upon third parties for various aspects of development and manufacturing.
• Risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company intends to discuss its registrational trial protocol (CRDF-005) with the FDA, aiming for accelerated and full approval based on ORR with DoR and PFS/lack of detriment on OS endpoints. An update on the first-line mCRC program is expected by Q1 2026. The company is optimistic about onvansertib's potential to redefine first-line treatment for RAS-mutated mCRC.

Management Comments

• "In the second quarter, we achieved an important milestone by completing enrollment in our ongoing CRDF-004 trial evaluating onvansertib plus standard of care for the treatment of first-line RAS-mutated mCRC." Mark Erlander, Chief Executive Officer.
• "As we evolve into a late-stage clinical development company, we were excited to appoint Dr. Sidhu as our new Chief Medical Officer to provide expert guidance in advancing onvansertib through the registrational phase of development. We're pleased to welcome him to the team and are confident that his expertise will be instrumental as we work toward bringing this potential therapy to patients." Mark Erlander, Chief Executive Officer.
• "We are highly encouraged by the 19% improvement in confirmed ORR as well as the shorter time to response and deeper tumor regression observed in our trial with onvansertib combined with SoC compared to SoC alone. Furthermore, early PFS data shows a trend favoring the 30mg dose of onvansertib vs. control." Roger Sidhu, MD, Chief Medical Officer.
• "The totality of the data we are releasing today strengthens the initial findings from our December 2024 data release in a significantly larger patient population, compares favorably to previous practice-changing Phase 3 trials, and demonstrates that onvansertib could be a novel therapy for the treatment of first-line RAS-mutated mCRC." Roger Sidhu, MD, Chief Medical Officer.
• "We are highly encouraged by the strength of our data which achieves the key objectives we set for the trial, and positions us to engage in discussions with the FDA as we advance toward our registrational CRDF-005 trial." Mark Erlander, Chief Executive Officer.
• "Looking ahead, we are optimistic about onvansertib's potential to redefine the first-line treatment for RAS-mutated mCRC and will provide an update on our first-line mCRC program by Q1 2026." Mark Erlander, Chief Executive Officer.

Industry Context

The announcement positions Cardiff Oncology's onvansertib as a promising novel therapy for first-line RAS-mutated metastatic colorectal cancer (mCRC), an area with high unmet need and limited therapeutic advancements since 2014. The positive Phase 2 data, particularly the significant improvement in ORR and dose-dependent effects, suggest onvansertib could offer a new treatment option for a patient population that currently relies on chemotherapy and bevacizumab. The focus on PLK1 inhibition targets a well-validated oncology pathway, potentially overcoming treatment resistance. The data also supports the broader applicability of onvansertib, as evidenced by positive results in mTNBC, indicating potential across multiple cancer types.

Comparison to Industry Standards

• The 30mg onvansertib dose arm demonstrated a 19% improvement in confirmed ORR (49% vs. 30% control) in first-line RAS-mutated mCRC, which compares favorably to historical Phase 3 trials.
• In the Bevacizumab (IFL/bev vs IFL) trial, the ORR delta for mutant-only patients was 2%, significantly lower than onvansertib's 19% delta.
• In the FOLFOXIRI/bev (TRIBE trial), the ORR delta for mutant-only patients was 11%, also lower than onvansertib's 19% delta.
• Onvansertib 30mg achieved 46% Early Tumor Shrinkage (ETS) compared to 22% for control, with a p-value of 0.038. This is a stronger ETS percentage than observed in the TRIBE (63% experimental vs 52% control, 11% delta), CRYSTAL (69% experimental vs 49% control, 20% delta), and OPUS (62% experimental vs 41% control, 21% delta) trials, considering the RAS-mutated population.
• Onvansertib 30mg achieved 48% Depth of Response (DpR) compared to 31% for control, with a p-value of 0.011. This DpR is also competitive with or superior to historical benchmarks from TRIBE (43% experimental vs 38% control, 5% delta), CRYSTAL (51% experimental vs 33% control, 18% delta), and OPUS (58% experimental vs 32% control, 26% delta) trials, especially given the challenging RAS-mutated patient population.

Management Changes

Stakeholder Impact

• **Shareholders:** Positive clinical trial results and extended cash runway are likely to increase investor confidence and potentially lead to share price appreciation. The significant increase in weighted-average shares outstanding suggests prior dilution, but the positive news may offset this.
• **Patients:** The positive data for onvansertib in RAS-mutated mCRC offers hope for a new, more effective treatment option for a patient population with high unmet needs.
• **Employees:** The company's progress in clinical development and extended financial runway provide stability and positive momentum for employees.
• **Regulatory Authorities (FDA):** The strong Phase 2 data provides a solid basis for discussions with the FDA regarding a registrational trial, potentially accelerating the path to market approval.

Next Steps

• Cardiff Oncology will host a conference call and webcast on July 29, 2025, to share updated clinical data from the CRDF-004 trial.
• The company intends to discuss its registrational trial protocol (CRDF-005) with the FDA.
• An update on the first-line mCRC program is expected by Q1 2026.

Key Dates

Recommendation

The filing presents compelling positive Phase 2 clinical trial data for onvansertib in first-line RAS-mutated mCRC, a high-unmet-need indication. The 19% improvement in confirmed ORR is statistically significant and compares favorably to historical benchmarks for similar therapies. The dose-dependent efficacy, favorable safety profile, and early PFS trends strongly position onvansertib for a registrational Phase 3 trial. Furthermore, the extended cash runway into Q1 2027 provides financial stability, and the appointment of a seasoned CMO strengthens the leadership team. These factors collectively indicate a high probability of future success and significant upside potential for the stock.

Keywords

Cardiff Oncology, CRDF, Onvansertib, PLK1 inhibitor, Metastatic Colorectal Cancer, mCRC, RAS-mutated, Clinical Trial, Phase 2, CRDF-004, Objective Response Rate, ORR, Progression-Free Survival, PFS, Oncology, Biotechnology, Drug Development, Cancer Therapy, Triple Negative Breast Cancer, mTNBC, Patent, Financial Results, Cash Runway, FDA, Clinical-stage